Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Needle-free tech enters Japanese growth hormone market:

This article was originally published in Clinica

Executive Summary

Antares Pharma has reported that its needle-free injection technology has become the first such product to enter the Japanese human growth hormone market. The firm's Japanese licensee, JCR Pharmaceuticals Co, of Ashiya, this month launched the Twin-Jector EZ II, a product that combines Antares' Vision needle-free technology with JCR's growth hormone. Japan represents the highest value market for human growth hormone products, said Antares CEO Roger Harrison. Antares' needle-free technology was launched in the European human growth hormone market in 1997. "For the year ended December 31 2003, the majority of our reported product revenues was derived from this sector of our business," Mr Harrison said. Under the deal with JCR, Antares will receive manufacturing margins on sales of devices as well as royalties on the end sales of human growth hormone used with the needle-free technology.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT059366

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel